FDA Publishes Guidance on Container Closure Systems for COVID-19
The document includes recommendations for the reporting and implementation of changes to container closure system components.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
On Nov. 7, 2023, FDA issued final guidance that includes recommendations for reporting post-approval changes of some common changes to container closure system (CCS) components consisting of glass vials and stoppers for approved sterile drug products and biologics. The recommendations apply to approved new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs). Pathways available to application holders to obtain feedback from FDA are also presented. Risk-based tools for implementation of changes to CCSs consisting of glass vials and stoppers are provided. This guidance does not apply to CCS types other than glass vials and stoppers.
According to FDA, many COVID-19 products use glass vials and stoppers as their CCS, and the supply of these products may be constrained. Manufacturers, therefore, may need to update approved applications to reflect changes made to CCS components to fill demand. The agency will consider risk-based approaches to implementation of chemistry, manufacturing, and controls (CMC) changes to a CCS so that supply of products is not impeded.
The guidance details common changes related to glass vials and stoppers and provides information on tools that can facilitate changes to CCS components. “FDA may expedite the assessment of a supplement or determine that a different reporting category is appropriate, taking into account public health priorities and the applicant’s rationale and associated risk assessment and mitigation strategy for the proposed change. Should a different reporting category be determined to be appropriate, FDA will notify the applicant and convey its rationale for the determination,” the agency states in the document.
The policy remains in effect until Aug. 7, 2024 unless a revised final guidance is published before then. More information can be found in the Federal Register at https://www.federalregister.gov/documents/2023/03/13/2023- 05094/guidance-documents-related-to-coronavirus-disease-2019-covid-19
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
